The purpose of this study is to determine the safety of EC1169 and the best dose to use in humans with recurrent Metastatic, Castration-Resistant Prostate Cancer (mCRPC). This study will also determine how EC1169 is distributed, broken down, passed and absorbed through your body and how quickly it is eliminated (leaves the body). All patients will receive EC1169.

Primary disease category: 

The TRUMPET registry is looking at how advanced prostate cancer is treated across the US. It is also exploring how treatments for prostate cancer can affect daily life.
Information will be collected at routine medical visits, and caregivers are also able to take part if they wish. Information from the TRUMPET Registry could help doctors learn how to better treat men living with prostate cancer in the future.

Primary disease category: 

This study is for the treatment of advanced solid tumors.

Primary disease category: 
Secondary disease category(ies): 


Subscribe to RSS - Cancer